Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales
Date
2015
Type:
Artículo
item.page.extent
item.page.accessRights
Authors
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Sociedad Médica de Santiago
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Prostate cancer represents the second cancer-related cause of death in North American and Chilean men. The main treatment for incurable stages of disease is surgical or pharmacological castration. However, with time and despite the addition of anti-androgens, the disease progresses to a clinical state that has been commonly referred to as “hormone refractory”. In recent years, the concept of hormone refractoriness has been challenged and replaced by “castration resistance”, acknowledging that further and optimal hormonal manipulation can be attained, beyond achieving testosterone levels at castration range. The purpose of this review is to summarize the recent therapeutic breakthroughs in the management of metastatic castrate resistant prostate cancer (mCRPC), with greater emphasis in the newer hormonal therapy agents such as Abiraterone and Enzalutamide. Future combination and sequential treatment strategies are contextualized in the current era of personalized cancer medicine and genomic characterization of prostate cancer.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Berlin, Alejandro, & Fernández, Mario I. (2015). Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales. Revista médica de Chile, 143(2), 223-236.
Keywords
Abiraterone, Enzalutamide, Prostatic neoplasms, castration-resistant